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Abstract
Background: Linear IgA bullous dermatosis (LABD) is a rare autoimmune subepithelial vesiculobullous disease due
to IgA autoantibodies directed against different antigens of the basement membrane zone (BMZ) of the skin
and/or mucosae. It affects mainly preschool-aged children and adults, with only few studies on large series.
The aim of this study was to assess possible differences between adults and children regarding clinical
presentation, immunopathologic features, management and course of the disease.
Methods: A retrospective review of 38 LABD patients, followed-up from November 2006 to September 2018,
was performed.
Results: Of 38 patients, 27 were adults and 11 children. Mean age at diagnosis was 5.4 years and 60.6 years
in the pediatric and adult group, respectively. Considering both groups, limbs were the most commonly
involved site (73.7%), followed by trunk (55.3%), head (36.8%) and buttocks (13.2%). Interestingly, head (p = 0.008),
particularly perioral (p = 0.001), involvement, as well as “string of pearls” arrangement (p = 0.03), were more
prevalent in children. Mucosal involvement was seen in 9 (23.7%) patients and was more frequent in children
than adults (45.5% vs 14.8%, respectively, p = 0.09). Linear IgA deposits along the BMZ were observed in 30
patients (78.9%), while linear/granular IgA deposits in 8 patients (21.1%). Dapsone was the most commonly used
drug (78.9%) and complete remission was achieved in most cases (81.6%).
Conclusions: Our epidemiological and clinicopathological findings relative to a large cohort of LABD patients are
mostly consistent with the literature data. Interestingly, head, notably perioral, involvement and “string of pearls”
arrangement occurred more frequently in the paediatric than adult group. The above clinical parameters may be
regarded as diagnostic tools for LABD in children.
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Background
Linear immunoglobulin A (IgA) bullous dermatosis
(LABD, ORPHA: 46488) is a rare autoimmune sube-
pithelial vesiculobullous disease caused by IgA autoanti-
bodies directed against different antigens of the
basement membrane zone (BMZ) of the skin and/or
mucosae [1, 2]. On direct immunofluorescence (DIF),
LABD is characterized by linear deposition of IgA along
the BMZ, with the possible presence of circulating IgA
anti-BMZ antibodies [3]. Both children and adults may
be affected, with a bimodal age of onset. In children,
LABD typically manifests as tense arciform blisters that
may show a “string of pearls” configuration and an ery-
thematous/urticarial base. The preferential sites are re-
ported to be the anogenital area and lower abdomen in
children, whilst the trunk and extensor surface of the
limbs in adults [1]. The childhood variant, formerly
known as chronic bullous disease of the childhood
(CBDC), has usually a self-healing course, albeit in few
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cases it may persist until adulthood [4–10]. Although in
the past the adult- and childhood-onset variants were
considered as distinct diseases, currently it is widely rec-
ognized that these two conditions share the same etio-
pathogenetic mechanisms and, consequently, have to be
unified into a single entity [1]. LABD is a rare disease
with an incidence ranging from 0.1 new cases per mil-
lion population in Germany [11] to 1.45 new cases per
million population in Uganda [12]. Mucous membrane
involvement, notably oral cavity and conjunctiva, is rela-
tively frequent, potentially leading to scarring sequelae
[3, 13–16]. LABD may be idiopathic or due to different
triggering factors, including drugs [15–17]. The mainstay
of therapy consists of dapsone. In refractory cases,
sulfapyridine may be combined or, alternatively, other
therapeutic strategies, such as systemic corticosteroids,
cyclosporine, colchicine, erythromycin, and intravenous
immunoglobulins, may be used [1].
Literature is lacking retrospective studies on LABD
from Italy, as only a few case reports have been pub-
lished [18–29]. Therefore, to expand the knowledge
about epidemiological aspects, clinicopathological fea-
tures, course and management of LABD, we retrospect-
ively studied patients followed-up at a single tertiary
care center in Milan (Northern Italy) in order to assess
the possible differences between adults and children.
Materials and methods
Patients and methods
We retrospectively examined medical records of LABD
patients admitted to our outpatient service from No-
vember 2006 to September 2018. The diagnosis of LABD
was rendered based on both clinical examination and
immunopathological criteria [2, 30]. Inclusion criteria
were: (i) presence of cutaneous manifestations consisting
of tense blisters and/or vesiculobullous lesions and/or
erosions, which might show a “string of pearls” configur-
ation, and/or urticaria-like or prurigo-like lesions, pos-
sibly associated with oral, conjunctival, nasal or genital
mucous membrane involvements consisting of blisters
and/or erosions (ii) DIF of perilesional skin showing lin-
ear or linear/granular IgA deposition along the BMZ
(when concomitant complement fraction 3 [C3c], IgG
and/or IgM deposits along the BMZ were observed on
DIF, the diagnosis of LABD was confirmed only if IgA
deposits were predominant). Indirect immunofluores-
cence (IIF) with salt-split skin was performed to detect
IgA and IgG deposits only in selected cases when the
diagnosis was uncertain. Patients with predominant/ex-
clusive mucosal manifestations were diagnosed as having
mucous membrane pemphigoid (MMP) based on the
diagnostic criteria set up in the first international con-
sensus on MMP [31]; therefore, they were excluded from
the study. In all patients with linear/granular IgA
deposits on DIF, a possible diagnosis of dermatitis herpe-
tiformis (DH) was ruled out on the basis of the negativ-
ity of serum IgA antibodies against both tissue
transglutaminase and endomysium. Clinical parameters
collected included sex, age at disease onset, comorbidi-
ties, pre-biopsy differential diagnosis, involved sites and
clinical presentation, management strategies, and out-
come at the last follow-up. Drug-induction was assessed
by means of Naranjo score (NS), with an at least prob-
able score (> 4) as the threshold to diagnose
drug-induced LABD [32]. “Complete remission” (CR)
was defined as the absence of new and/or established le-
sions for at least 2 months without or with minimal
therapy. “Minimal therapy” was considered as less than
or equal to 0.2 mg/kg/day of dapsone and/or 0.1 mg/kg/
day of prednisone (or the equivalent) and/or minimal
adjuvant or maintenance therapy. “Partial remission”
(PR) was defined as the presence of transient (healing
within a week) new lesions without or with minimal
therapy, as defined above. No response (NR) was defined
as the presence of persistent (not healing within a week)
new lesions despite therapy (Additional file 1: Table S1).
Relapses were defined as the reappearance of LABD
manifestations in patients who showed an at least
4-month duration CR.
Statistical analysis
Categorical variables are reported as number (percent-
age), and continuous variables as mean (range). Data
analysis was performed with Fisher’s exact test, as appro-
priate, using GraphPad Prism version 6.0 (GraphPad
Software, Inc., San Diego, CA). Statistical significance
was defined as p ≤ 0.05.
Results
Patients and clinical findings
Detailed clinical and laboratory data of the 38 collected
patients are shown in Additional file 1: Table S1 in-
cluded in the manuscript as additional file. They had an
average age at diagnosis of 45.7 years (range 0.9–93
years). In the 11 patients (28.9%) diagnosed before 16
years old, the mean age at diagnosis was 5.4 years, while
in the adult group it was 60.6 years. The overall male to
female ratio was 1.2. It was lower in adults (0.9) than in
children (2.7), even though, as shown in Table 1, there
were no statistically significant differences in sex pre-
ponderance between adults and children. Concerning
comorbidities, four patients had a history of neoplasm,
two were affected by ulcerative colitis and one by coeliac
disease. This last patient displayed linear/granular IgA
deposits, making it mandatory to rule out DH. Thus, we
performed salt-split skin IIF that showed linear IgA de-
posits along the epidermal side of the BMZ, consistent
with LABD. At the time of diagnosis, bullous and/or
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vesiculobullous elements on erythematous (Fig. 1b and
d) or non-inflamed skin represented the most commonly
observed (n = 35; 92.1%) skin lesions. The “string of
pearls” arrangement (Fig. 1a and c) was described in 8 pa-
tients (21.1%) and resulted significantly more frequent in
children than in adults (45.5% vs 11.1%; p = 0.03), as
shown in Table 1. In a single case, only urticaria-like
lesions were present, while in two cases crusts, erosions
and excoriated lesions were the only cutaneous findings.
Skin lesions were located on the limbs (n = 28: 73.7%),
Table 1 Clinical and laboratory characteristic of adults and children with LABD
Characteristic Adults (n = 27) Children (n = 11) p-value
Male patients 13 (48.1) 8 (72.7) 0.28
Mean age at diagnosis (years) 60.6 5.4 –
“String of pearls” pattern 3 (11.1) 5 (45.5) 0.03*
Mucosal involvement 4 (14.8) 5 (45.5) 0.09
Head involvement (excluded mucosae) 6 (22.2) 8 (72.7) 0.008*
Perioral involvement 1 (3.7) 6 (54.5) 0.001*
Scalp involvement 4 (14.8) 0 0.3
Limbs 20 (74.1) 8 (72.7) 0.93
Trunk 15 (55.6) 6 (54.5) 1
Buttocks 4 (14.8) 1 (9.1) 1
Drug-induction 1 (3.7) 1 (9.1) 0.5
Eosinophils on histopathology 17 (62.7) 5 (45.5) 0.47
Linear IgA along the BMZ at DIF 21 (77.8) 9 (81.8) 1
Linear/granular IgA along the BMZ at DIF 6 (22.2) 2 (9.1) 1
C3c deposits at DIF 7 (25.9) 4 (36.4) 0.7
Salt-split skin IIF positivity for linear IgAa 13 (43.5) 6 (85.7) 0.21
CRb 21 (84) 10 (90.9) 1
PRb 2 (8) 1 (9.1) 1
NRb 2 (8) 0 1
Relapsesb 4 (16) 1 (9.1) 1
Values are expressed as n (%); C3c, complement fraction 3; CR, complete remission; DIF, direct immunofluorescence; IIF, indirect immunofluorescence; NR, no
response; PR: partial remission; a, performed in only 30 patients (23 adults and 7 children); b, 2 patients lost at follow-up; *, statistically significant
Fig. 1 Linear IgA bullous dermatosis. a Widespread vesiculobullous eruption on the lower limbs with elements in a “string of pearls” arrangement; (b)
targetoid vesicular lesions on erythematous skin involving the dorsa of the hands; (c) blisters with a “string of pearls” configuration and crusts in the
perioral area; (d) erythematous, vesicular lesions partially eroded on the posterior aspects of both thighs; (e) vesicles involving the vulvar area in a child
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trunk (n = 21; 55.3%), head (n = 14; 36.8%) and buttocks
(n = 5; 13.2%). Head involvement was more common in
children than adults (72.7% vs 22.2%; p = 0.008) and, when
considering only the perioral area, the statistical signifi-
cance increased (54.5% vs 3.7%; p = 0.001). Mucous mem-
brane involvement was observed in 9 (23.7%) patients and
the most frequent mucosal localisation was oral cavity
(15.8%), followed by genital (7.8%) (Fig. 1e), conjunctival
(5.2%) and nasal cavity (2.6%) involvements. Mucosae
were more frequently involved in children than adults
(45.5% vs 14.8%, respectively; p = 0.09) and, interestingly,
all patients with genital involvement (n = 3) were children.
Pre-biopsy diagnostic hypothesis was correct in 7 cases
(18.4%), while bullous pemphigoid (BP) (n = 10; 26.3%)
and bullous impetigo (n = 5; 13.2%) represented the most
frequent misdiagnoses. All but two cases were idiopathic;
the two probably drug-induced cases were triggered by
amoxicillin/clavulanic acid (NS = 6) and clarithromycin
(NS = 5), with a latency time from the intake of 1 and 3
weeks, respectively. Losartan (NS = 2), oxcarbazepine (NS
= 3) and chlorambucil (NS = 2) were regarded as possible
culprit drugs in three other cases.
Histology and immunofluorescence results
Histological examination on skin or mucous biopsies as
well as DIF examination were routinely performed in all
patients. On histopathological assessment, all cases re-
vealed subepidermal blisters associated with dermal infil-
trate of neutrophils. In 22 cases (57.9%), eosinophils
were observed in association with neutrophils in the
upper dermis, without statistically significant differences
between adults and children (p = 0.47). Neutrophil
microabscesses at the tip of the dermal papillae were
seen in three cases (7.9%).
On DIF, linear IgA deposits along the BMZ were
observed in 30 patients (78.9%), while linear/granular
IgA deposits were detected in 8 patients (21.1%). As
shown in Table 1, no statistically significant differ-
ences were observed between adults and children in
terms of positivity for linear or linear/granular IgA
deposits. Linear deposits of IgA alone - with neither
Ig class other than IgA nor complement - were ob-
served in 23 cases, while linear/granular deposits of
IgA alone were observed in three cases. Among the
12 cases showing deposits of Ig other than IgA or
complement in addition to IgA, 11 patients had C3c,
6 had IgM and 3 had IgG. Salt-split human skin IIF
was performed in 30 patients and was positive in 19
out of 30 cases (63.3%), all showing linear IgA de-
posits along the epidermal side of the BMZ. All cases
were negative for IgG deposits on salt-split human
skin IIF. Children had a higher, albeit not statistically
significant, positivity rate of salt-split human skin IIF
compared to adults (85.7% vs 43.5%; p = 0.21).
Treatment and follow-up
All patients except two self-resolving cases received sys-
temic therapy, combined with topical treatment in some
cases. Dapsone, administered to 30 patients (78.9%),
with a mean starting dosage of 0.5 mg/kg per day, was
the most common treatment option. Median duration of
dapsone treatment was 26.2 months. We observed
dapsone-induced methemoglobinemia only in a patient,
who was switched to oral methylprednisolone and con-
sequently showed a CR. Systemic corticosteroids (pred-
nisone, oral and intravenous methylprednisolone, and
deflazacort) were given in concomitance with, preceding
or following dapsone in 22 cases (57.9%), while in 5
cases (13.2%) they represented a stand-alone therapy. In
a case resistant to corticosteroid monotherapy, a com-
bination of methotrexate and oral methylprednisolone
induced a CR. Other treatment options for
steroid-refractory cases are reported in Additional file 1:
Table S1. Topical steroids were given to 6 patients, with
clobetasol propionate being the most commonly used
agent (n = 4; 10.5%). Cyclosporine eye drops were ad-
ministered in two patients with ocular involvement. One
adult patient with a drug-induced form and one
pediatric patient received neither systemic nor topical
treatments owing to a self-limiting course, with a
follow-up time of 16 months in both cases. The mean
follow-up time was 30.7 months. CR was achieved in
most cases (n = 31; 81.6%), while PR in three patients.
Only two cases were refractory to multiple drugs, show-
ing NR (Additional file 1: Table S1). Scarring sequelae
were observed in two cases showing aggressive conjunc-
tival involvement. Relapses were observed in five patients
(adults, n = 4; children, n = 1), with no statistically signifi-
cant differences between adults and children. All patients
with relapsed disease were not taking any medication for
their LABD at the moment of the relapse. The mean time
from drug withdrawal to relapse was 10months. All pa-
tients who experienced a relapse re-achieved a CR after
treatment reintroduction. As shown in Table 1, no statisti-
cally significant differences were found between the adult
and pediatric group in terms of response to treatment.
Discussion
We present the largest case-series of Italian patients
with LABD and compare our findings with data re-
ported in the literature (Additional file 2: Table S2).
Our results confirmed the bimodal age at onset of
this disease [1], with two different groups represented
by children and adults. Although an overall similar
prevalence in males and females was outlined, strati-
fying the population in terms of age, our data re-
vealed a preponderance of the disease, albeit not
statistically significant, in male children, as already
observed by other authors [7–9].
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Regarding clinical manifestations, of note, in our study
head, particularly perioral, involvements were signifi-
cantly more common in the pediatric than adult group
(72.7% vs 22.2%; p = 0.008 and 54.5% vs 3.7%; p = 0.001,
respectively). This is in line with literature data reporting
the head and face more commonly involved in children
than adults [6]. Furthermore, the “string of pearls” ar-
rangement was significantly more frequent in children
than adults (p = 0.03), similarly to the findings of
Jabłońska et al. [5], with an overall prevalence of 21%.
Consistent with data reporting high prevalences of geni-
tal involvement in the pediatric population [5], all pa-
tients with genital involvement were children.
Gottlieb et al. [14] showed that 60% of a case series of
72 adults with LABD had mucous membrane involve-
ment, suggesting that the term “linear IgA disease”
might be more suitable than “linear IgA dermatosis”. On
the other hand, data about mucous membrane involve-
ment in children are controversial, since a study by Woj-
narowska et al. [6] disclosed a prevalence of mucosal
involvement of 64% in 25 LABD children, but more re-
cent case series revealed lower prevalences [9, 10, 33]. In
our study, mucosal involvement resulted less common
than that reported by Wojnarowska et al. [6] and it was
more frequent in children than adults (45.5% vs 14.8%,
respectively), albeit without statistically significant
difference.
We regarded drugs as a probable or possible cause of
LABD in 13.2% of our cohort, a lower prevalence as
compared to the study of Lings et al., which identified
possibly/probably drug-induced LABD in 6 out of 23
(26.1%) cases [34]. Although both Chanal et al. [16] and
Garel et al. [15] concluded in two independent retro-
spective studies that drug-induced LABD might be more
severe and mimic toxic epidermal necrolysis (TEN), both
our drug-induced cases lacked TEN-like features and
achieved a CR upon treatment.
The increasingly described association of LABD
with inflammatory bowel diseases [35–37] was con-
firmed by our study, showing an ulcerative colitis
prevalence of 5.6%, much higher than 0.12% estimated
in the Italian general population [38]. Immune activa-
tion secondary to the exposition of multiple intestinal
epithelial antigens, included BP180, in patients with
coexistence of LABD and inflammatory bowel dis-
eases has been hypothesized as a possible pathome-
chanism eliciting blister formation [35].
Approximately 15% of the adult patients had a history
of cancer. Although malignancies, especially of lympho-
reticular origin, have been described in association with
LABD, [39] in all our cases the lack of a close temporal
relationship between the onset of LABD and the under-
lying neoplasm made it unlikely the hypothesis of a
paraneoplastic disease.
Linear IgA deposition along the BMZ with neither Ig
class other than IgA nor complement resulted the most
frequent pattern on DIF in our case series. In our study,
patients with linear IgG deposits in addition to linear
IgA deposits were considered as a subgroup of LABD.
Indeed, Ohata et al. [3] suggested linear IgA/IgG bullous
dermatosis as part of a spectrum of diseases ranging
from LABD to BP.
IIF on human skin has been reported to be positive for
IgA in just over 80% of children and approximately 40%
of adults [40] and salt-split skin technique demonstrated
an increase in the sensitivity of IIF [3, 14, 40]. In our
study, salt-split skin IIF resulted positive in approxi-
mately 60% of patients and, in line with the results of
Willsteed et al. [40], a higher, albeit not statistically sig-
nificant, rate of positivity of salt-split skin IIF was ob-
served in children as compared to adults (85.7% vs
43.5%, respectively). Moreover, all our cases showed an
epidermal binding. Although IgA deposits on salt-split
skin are predominantly detected on the epidermal side
[40], dermal binding has been reported in 8% [3] and
17% [41] of large case series. In the study by Ohata et
al. [3], binding of IgA autoantibodies to both sides of the
split was observed only in 7% of patients.
Most frequent and successful treatment was dapsone,
given both as a stand-alone therapy and combined with
systemic steroids. In our comparison of the adult and
children group, we failed to identify any differences in
terms of response to treatment. As compared to the
study of Gottlieb et al., [14] higher CR and lower relapse
rates were observed in our patients. These differences
might be due to a combination of the following aspects:
(i) only adults, usually showing a more aggressive and
relapsing course, have been collected in the study of
Gottlieb et al.; (ii) as opposed to our study, cases with
predominant mucous membrane involvement, also
showing a more refractory behaviour, have been in-
cluded; (iii) topical corticosteroids were the first-choice
treatment in 40% of their patients, while almost all our
patients received systemic treatments as first-line.
The main limitation of the present study was its retro-
spective nature, which, however, depended on the rarity of
the disease. Furthermore, a direct comparison between
the two groups might have been biased by the fact that
adults were more numerous than children in the study
population. An additional limitation was represented by
the fact that immunoblotting and enzyme-linked im-
munoassay for BP180, BP230 and/or collagen VII were
not performed. Therefore, it cannot be stated with cer-
tainty whether cases of sublamina densa-type LABD and
IgA-epidermolysis bullosa acquisita, whose common auto-
antigen is collagen VII, [42–44] have been missed. Fur-
thermore, establishing an accurate diagnosis of LABD
may be difficult owing to the absence of unanimous
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consensus on diagnostic criteria. [45] In this regard, we
ruled out from our study patients with linear or linear/
granular IgA deposits on DIF and predominant/exclusive
mucosal involvement, who, based on the first consensus
conference on MMP, were classified as having IgA-MMP.
[31, 46] Although our criteria may have been strict and
are not fully in line with those adopted in other large
series on LABD [3, 14], we believe that they are clear and
have minimal risk of including MMP patients.
Conclusion
In summary, the results of this retrospective study
conducted on a cohort of 38 Italian LABD patients
diagnosed and followed-up in a single center con-
firmed the biphasic age at onset of the disease and
showed a higher prevalence of head, particularly peri-
oral, and mucosal involvements as well as a more fre-
quent “string of pearls” arrangement in children than
adults. Thus, these clinical parameters may be a diag-
nostic tool for LABD in children.
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